How should we sequence and combine novel therapies in CLL?

le Davids, Matthew S.
Foilsithe in Hematology Am Soc Hematol Educ Program (2017)

ABT-199: A New Hope for Selective BCL-2 Inhibition

le Davids, Matthew S., Letai, Anthony
Foilsithe 2013

Targeting the B-Cell Lymphoma/Leukemia 2 Family in Cancer

le Davids, Matthew S., Letai, Anthony
Foilsithe in J Clin Oncol (2012)

IGHV Mutational Status Testing in Chronic Lymphocytic Leukemia

le Crombie, Jennifer, Davids, Matthew S.
Foilsithe in Am J Hematol (2017)

Cell Trafficking in Chronic Lymphocytic Leukemia

le Davids, Matthew S., Burger, Jan A.
Foilsithe 2012

Phosphoinositide 3-Kinase Inhibition in Chronic Lymphocytic Leukemia

le Davids, Matthew S., Brown, Jennifer R.
Foilsithe 2013

Targeting the B Cell Receptor Pathway in Chronic Lymphocytic Leukemia

le Davids, Matthew S., Brown, Jennifer R.
Foilsithe in Leuk Lymphoma (2012)

Ibrutinib: a first in class covalent inhibitor of Bruton’s tyrosine kinase

le Davids, Matthew S, Brown, Jennifer R
Foilsithe in Future Oncol (2014)

BCL-2 Antagonism to Target the Intrinsic Mitochondrial Pathway of Apoptosis

le Gibson, Christopher J., Davids, Matthew S.
Foilsithe in Clin Cancer Res (2015)

The Development and Current Use of BCL-2 Inhibitors for the Treatment of Chronic Lymphocytic Leukemia

le Lampson, Benjamin L., Davids, Matthew S.
Foilsithe in Curr Hematol Malig Rep (2017)

Safety profiles of novel agent therapies in CLL

le Ahn, Inhye E., Davids, Matthew S.
Foilsithe in Hematology Am Soc Hematol Educ Program (2017)

Overcoming stroma-mediated treatment resistance in chronic lymphocytic leukemia through BCL-2 inhibition

le Davids, Matthew S., Letai, Anthony, Brown, Jennifer R.
Foilsithe in Leuk Lymphoma (2013)

Bruton’s tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia

le Deng, Jing, Isik, Elif, Fernandes, Stacey M., Brown, Jennifer R., Letai, Anthony, Davids, Matthew S.
Foilsithe in Leukemia (2017)

Review of targeted therapy in chronic lymphocytic leukemia: what a radiologist needs to know about CT interpretation

le Gosangi, Babina, Davids, Matthew, Somarouthu, Bhanusupriya, Alessandrino, Francesco, Giardino, Angela, Ramaiya, Nikhil, Krajewski, Katherine
Foilsithe in Cancer Imaging (2018)

Pneumocystis jirovecii pneumonia and institutional prophylaxis practices in CLL patients treated with BTK inhibitors

le Ryan, Christine E., Cheng, Matthew P., Issa, Nicolas C., Brown, Jennifer R., Davids, Matthew S.
Foilsithe in Blood Adv (2020)

BTK inhibitors in cancer patients with COVID19: “The winner will be the one who controls that chaos” (Napoleon Bonaparte)

le Chong, Elise A., Roeker, Lindsey E., Shadman, Mazyar, Davids, Matthew S., Schuster, Stephen J., Mato, Anthony R.
Foilsithe in Clin Cancer Res (2020)

The redox-senescence axis and its therapeutic targeting

le Ngoi, Natalie YL., Liew, Angeline QX., Chong, Stephen J.F., Davids, Matthew S., Clement, Marie-Veronique, Pervaiz, Shazib
Foilsithe in Redox Biol (2021)

Systematic Literature Review of Economic Evaluations, Costs/Resource Use, and Quality of Life in Patients with Mantle Cell Lymphoma

le Monga, Neerav, Garside, Jamie, Davids, Matthew S., Tam, Constantine, Ward, Katherine, Fotheringham, Iain, O’Donovan, Peter, Parisi, Lori, Tapprich, Christoph
Foilsithe in Pharmacoecon Open (2020)

Synchronous squamous cell carcinoma and diffuse large B-cell lymphoma of the head and neck: the odd couple

le Raldow, Ann C, Brown, Johann G, Chau, Nicole, Davids, Matthew S, Margalit, Danielle N, Tishler, Roy B, Ng, Andrea, Schoenfeld, Jonathan D
Foilsithe in BJR Case Rep (2016)

Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia

le Davids, Matthew S., Deng, Jing, Wiestner, Adrian, Lannutti, Brian J., Wang, Lili, Wu, Catherine J., Wilson, Wyndham H., Brown, Jennifer R., Letai, Anthony
Foilsithe 2012